The stock of Tissue Regenix Group PLC (LON:TRX) is a huge mover today! The stock decreased 1.16% or GBX 0.19 on November 24, hitting GBX 15.94. About 135,961 shares traded hands. Tissue Regenix Group PLC (LON:TRX) has declined 20.37% since April 26, 2016 and is downtrending. It has underperformed by 25.78% the S&P500.
The move comes after 7 months positive chart setup for the GBX 120.26M company. It was reported on Nov, 24 by Barchart.com. We have GBX 17.37 PT which if reached, will make LON:TRX worth GBX 10.82 million more.
Tissue Regenix Group PLC (LON:TRX) Ratings Coverage
Out of 2 analysts covering Tissue Regenix Group PLC (LON:TRX), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Tissue Regenix Group PLC has been the topic of 15 analyst reports since October 12, 2015 according to StockzIntelligence Inc. The company was maintained on Monday, July 4 by Beaufort Securities. The firm has “Speculative Buy” rating by Beaufort Securities given on Thursday, March 10. As per Tuesday, July 12, the company rating was maintained by Beaufort Securities. The stock of Tissue Regenix Group PLC (LON:TRX) has “Buy” rating given on Tuesday, May 24 by Jefferies. On Monday, December 7 the stock rating was maintained by Beaufort Securities with “Speculative Buy”. The stock of Tissue Regenix Group PLC (LON:TRX) has “Speculative Buy” rating given on Thursday, January 21 by Beaufort Securities. On Thursday, October 13 the stock rating was maintained by Beaufort Securities with “Speculative Buy”. Jefferies maintained Tissue Regenix Group PLC (LON:TRX) on Monday, October 12 with “Buy” rating. The firm has “Speculative Buy” rating by Beaufort Securities given on Tuesday, May 24. Jefferies maintained the stock with “Buy” rating in Monday, January 18 report.
More notable recent Tissue Regenix Group PLC (LON:TRX) news were published by: Businesswire.com which released: “Tissue Regenix Group plc: DermaPure® – Two Peer Reviewed Clinical Papers Published” on September 15, 2016, also Uk.Finance.Yahoo.com with their article: “Tissue Regenix Group Plc (TRX.L)” published on March 30, 2014, Fool.Co.Uk published: “Are GlaxoSmithKline plc, Tissue Regenix Group plc and Optibiotix Health plc …” on May 23, 2016. More interesting news about Tissue Regenix Group PLC (LON:TRX) were released by: Businesswire.com and their article: “Pioneering global regenerative medical technology company, Tissue Regenix …” published on May 13, 2016 as well as Prnewswire.com‘s news article titled: “Tissue Regenix Group plc: Further Medicare Coverage Approval for DermaPure®” with publication date: May 11, 2015.
Tissue Regenix Group plc is a medical technology company. The company has a market cap of 120.26 million GBP. The Firm is engaged in the development of regenerative products to make replacement native tissue using biological tissues. It currently has negative earnings. It operates through Cardiac, Wound Care and Orthopaedics divisions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.